Algernon Pharmaceuticals Inc
Algernon Health Inc. operates as a clinical stage pharmaceutical development company in Canada and Australia. The company focuses on developing the therapeutic drugs in the areas of non-alcoholic steatohepatitis, liver disease, chronic kidney disease, and stroke program. Its pipeline includes repirinast for the treatment of chronic kidney disease; and N,N-Dimethyltryptamine for the treatment of s… Read more
Algernon Pharmaceuticals Inc (AGNPF) - Net Assets
Latest net assets as of November 2025: $2.49 Million USD
Based on the latest financial reports, Algernon Pharmaceuticals Inc (AGNPF) has net assets worth $2.49 Million USD as of November 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.93 Million) and total liabilities ($2.44 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.49 Million |
| % of Total Assets | 50.43% |
| Annual Growth Rate | 2.69% |
| 5-Year Change | -70.43% |
| 10-Year Change | N/A |
| Growth Volatility | 101.02 |
Algernon Pharmaceuticals Inc - Net Assets Trend (2016–2025)
This chart illustrates how Algernon Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Algernon Pharmaceuticals Inc (2016–2025)
The table below shows the annual net assets of Algernon Pharmaceuticals Inc from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-08-31 | $2.70 Million | +24.28% |
| 2024-08-31 | $2.17 Million | +47.13% |
| 2023-08-31 | $1.47 Million | -73.80% |
| 2022-08-31 | $5.62 Million | -38.29% |
| 2021-08-31 | $9.12 Million | -25.39% |
| 2020-08-31 | $12.22 Million | +145.68% |
| 2019-08-31 | $4.97 Million | +264.07% |
| 2018-08-31 | $1.37 Million | -14.03% |
| 2017-08-31 | $1.59 Million | -25.15% |
| 2016-08-31 | $2.12 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Algernon Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2326203900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (August 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $33.26 Million | 1234.02% |
| Total Equity | $2.70 Million | 100.00% |
Algernon Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Algernon Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Etga Group Ltd
TA:ETGA
|
$1.71 Million |
|
OBAL11
SA:OBAL11
|
$1.72 Million |
|
WestKam Gold Corp
PINK:WKGFF
|
$1.72 Million |
|
STAGEZERO LIFE SCIENC.
F:61N1
|
$1.72 Million |
|
CLASS 1 NICKEL+TECH.LTD
F:77C
|
$1.71 Million |
|
Identitii Ltd
AU:ID8
|
$1.71 Million |
|
Prima Alloy Steel Universal
JK:PRAS
|
$1.71 Million |
|
Webco Industries Inc
PINK:WEBC
|
$1.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Algernon Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,168,593 to 2,695,234, a change of 526,641 (24.3%).
- Net loss of 1,717,055 reduced equity.
- New share issuances of 587,100 increased equity.
- Other factors increased equity by 1,656,596.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.72 Million | -63.71% |
| Share Issuances | $587.10K | +21.78% |
| Other Changes | $1.66 Million | +61.46% |
| Total Change | $- | 24.28% |
Book Value vs Market Value Analysis
This analysis compares Algernon Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.79x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.07x to 0.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-08-31 | $0.06 | $0.06 | x |
| 2018-08-31 | $0.05 | $0.06 | x |
| 2019-08-31 | $0.11 | $0.06 | x |
| 2020-08-31 | $0.09 | $0.06 | x |
| 2021-08-31 | $5.44 | $0.06 | x |
| 2022-08-31 | $2.39 | $0.06 | x |
| 2023-08-31 | $0.09 | $0.06 | x |
| 2024-08-31 | $0.08 | $0.06 | x |
| 2025-08-31 | $0.08 | $0.06 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Algernon Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -63.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.81x
- Recent ROE (-63.71%) is above the historical average (-135.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -323.96% | 0.00% | 0.00x | 1.07x | $-7.09 Million |
| 2017 | -119.00% | 0.00% | 0.00x | 1.03x | $-2.05 Million |
| 2018 | -68.64% | 0.00% | 0.00x | 1.04x | $-1.07 Million |
| 2019 | -38.12% | 0.00% | 0.00x | 1.07x | $-2.39 Million |
| 2020 | -69.89% | 0.00% | 0.00x | 1.05x | $-9.76 Million |
| 2021 | -84.85% | 0.00% | 0.00x | 1.11x | $-8.65 Million |
| 2022 | -107.64% | 0.00% | 0.00x | 1.45x | $-6.62 Million |
| 2023 | -460.07% | 0.00% | 0.00x | 2.85x | $-6.93 Million |
| 2024 | -23.19% | 0.00% | 0.00x | 1.82x | $-719.84K |
| 2025 | -63.71% | 0.00% | 0.00x | 1.81x | $-1.99 Million |
Industry Comparison
This section compares Algernon Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Algernon Pharmaceuticals Inc (AGNPF) | $2.49 Million | -323.96% | 0.98x | $1.71 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |